FEBS Open Bio (Apr 2023)

Establishment of a risk score model for bladder urothelial carcinoma based on energy metabolism‐related genes and their relationships with immune infiltration

  • Caihong Huang,
  • Yexin Li,
  • Qiang Ling,
  • Chunmeng Wei,
  • Bo Fang,
  • Xingning Mao,
  • Rirong Yang,
  • LuLu Zhang,
  • Shengzhu Huang,
  • Jiwen Cheng,
  • Naikai Liao,
  • Fubo Wang,
  • Linjian Mo,
  • Zengnan Mo,
  • Longman Li

DOI
https://doi.org/10.1002/2211-5463.13580
Journal volume & issue
Vol. 13, no. 4
pp. 736 – 750

Abstract

Read online

Bladder urothelial carcinoma (BLCA) is a common malignant tumor of the human urinary system, and a large proportion of BLCA patients have a poor prognosis. Therefore, there is an urgent need to find more efficient and sensitive biomarkers for the prognosis of BLCA patients in clinical practice. RNA sequencing (RNA‐seq) data and clinical information were obtained from The Cancer Genome Atlas, and 584 energy metabolism‐related genes (EMRGs) were obtained from the Reactome pathway database. Cox regression analysis and least absolute shrinkage and selection operator analysis were applied to assess prognostic genes and build a risk score model. The estimate and cibersort algorithms were used to explore the immune microenvironment, immune infiltration, and checkpoints in BLCA patients. Furthermore, we used the Human Protein Atlas database and our single‐cell RNA‐seq datasets of BLCA patients to verify the expression of 13 EMRGs at the protein and single‐cell levels. We constructed a risk score model; the area under the curve of the model at 5 years was 0.792. The risk score was significantly correlated with the immune markers M0 macrophages, M2 macrophages, CD8 T cells, follicular helper T cells, regulatory T cells, and dendritic activating cells. Furthermore, eight immune checkpoint genes were significantly upregulated in the high‐risk group. The risk score model can accurately predict the prognosis of BLCA patients and has clinical application value. In addition, according to the differences in immune infiltration and checkpoints, BLCA patients with the most significant benefit can be selected for immune checkpoint inhibitor therapy.

Keywords